Distinct but complementary contributions of PPAR isotypes to energy homeostasis
- PMID: 28368286
- PMCID: PMC5373878
- DOI: 10.1172/JCI88894
Distinct but complementary contributions of PPAR isotypes to energy homeostasis
Abstract
Peroxisome proliferator-activated receptors (PPARs) regulate energy metabolism and hence are therapeutic _targets in metabolic diseases such as type 2 diabetes and non-alcoholic fatty liver disease. While they share anti-inflammatory activities, the PPAR isotypes distinguish themselves by differential actions on lipid and glucose homeostasis. In this Review we discuss the complementary and distinct metabolic effects of the PPAR isotypes together with the underlying cellular and molecular mechanisms, as well as the synthetic PPAR ligands that are used in the clinic or under development. We highlight the potential of new PPAR ligands with improved efficacy and safety profiles in the treatment of complex metabolic disorders.
Conflict of interest statement
Figures
Similar articles
-
PPARs in obesity-induced T2DM, dyslipidaemia and NAFLD.Nat Rev Endocrinol. 2017 Jan;13(1):36-49. doi: 10.1038/nrendo.2016.135. Epub 2016 Sep 16. Nat Rev Endocrinol. 2017. PMID: 27636730 Review.
-
Peroxisome Proliferator-Activated Receptors and Their Novel Ligands as Candidates for the Treatment of Non-Alcoholic Fatty Liver Disease.Cells. 2020 Jul 8;9(7):1638. doi: 10.3390/cells9071638. Cells. 2020. PMID: 32650421 Free PMC article. Review.
-
Anti-NASH Drug Development Hitches a Lift on PPAR Agonism.Cells. 2019 Dec 21;9(1):37. doi: 10.3390/cells9010037. Cells. 2019. PMID: 31877771 Free PMC article. Review.
-
A review of the studies on food-derived factors which regulate energy metabolism via the modulation of lipid-sensing nuclear receptors.Biosci Biotechnol Biochem. 2019 Apr;83(4):579-588. doi: 10.1080/09168451.2018.1559025. Epub 2018 Dec 20. Biosci Biotechnol Biochem. 2019. PMID: 30572788 Review.
-
Role of peroxisome proliferator-activated receptors in non-alcoholic fatty liver disease inflammation.Cell Mol Life Sci. 2018 Aug;75(16):2951-2961. doi: 10.1007/s00018-018-2838-4. Epub 2018 May 22. Cell Mol Life Sci. 2018. PMID: 29789866 Free PMC article. Review.
Cited by
-
Multifaceted regulation of hepatic lipid metabolism by YY1.Life Sci Alliance. 2021 Jun 7;4(7):e202000928. doi: 10.26508/lsa.202000928. Print 2021 Jul. Life Sci Alliance. 2021. PMID: 34099540 Free PMC article.
-
BAR502/fibrate conjugates: synthesis, biological evaluation and metabolic profile.Front Chem. 2024 Jul 17;12:1425867. doi: 10.3389/fchem.2024.1425867. eCollection 2024. Front Chem. 2024. PMID: 39086986 Free PMC article.
-
Metabolic Alterations Associated with Atorvastatin/Fenofibric Acid Combination in Patients with Atherogenic Dyslipidaemia: A Randomized Trial for Comparison with Escalated-Dose Atorvastatin.Sci Rep. 2018 Oct 2;8(1):14642. doi: 10.1038/s41598-018-33058-x. Sci Rep. 2018. PMID: 30279504 Free PMC article. Clinical Trial.
-
C/EBPα promotes triacylglycerol synthesis via regulating PPARG promoter activity in goat mammary epithelial cells.J Anim Sci. 2023 Jan 3;101:skac412. doi: 10.1093/jas/skac412. J Anim Sci. 2023. PMID: 36547378 Free PMC article.
-
Peroxisome Proliferator-Activated Receptors Regulate Hepatic Immunity and Assist in the Treatment of Primary Biliary Cholangitis.Front Immunol. 2022 Jul 8;13:940688. doi: 10.3389/fimmu.2022.940688. eCollection 2022. Front Immunol. 2022. PMID: 35880178 Free PMC article. Review.
References
-
- Gross B, Pawlak M, Lefebvre P, Staels B. PPARs in obesity-induced T2DM, dyslipidaemia and NAFLD. Nat Rev Endocrinol. 2017;13(1):36–49. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical